지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2010.1
- 수록면
- 1 - 8 (8page)
이용수
초록· 키워드
오류제보하기
The strategies of incorporating monoclonal antibodies (MoABs) have now proved efficacy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). These include targeting the vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR). Bevacizumab is a MoAB targeting the vascular endothelial growth factor (VEGF), an important mediator of new blood vessel formation. Cetuximab is a MoAB directed at EGFR. Binding cetuximab to EGFR blocks signal transduction and promotes receptor internalization and degradation. In this review, we present current data of bevacizumab and cetuximab for the first line treatment of advanced NSCLC. We also refer to their potential for Asian patients with advanced NSCLC in the first-line setting.
목차
등록된 정보가 없습니다.
참고문헌 (17)
참고문헌 신청
Akerley WL / 2008 / Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer / J Clin Oncol 26
Archer V / 2008 / Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with nonsquamous non-small cell lung cancer (NSCLC) recei
Dansin E / 2008 / Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390
Dowlati A / 2008 / Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with ch
Gordon MS / 2001 / Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer / J Clin Oncol 19 :
Archer V / 2008 / Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with nonsquamous non-small cell lung cancer (NSCLC) recei
Dansin E / 2008 / Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390
Dowlati A / 2008 / Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with ch
Gordon MS / 2001 / Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer / J Clin Oncol 19 :
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
진행성 비소세포폐암의 표적치료 및 맞춤항암치료
대한내과학회지
2009 .01
-
Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Cancer Research and Treatment
2015 .01
-
표준 항암화학요법에 실패한 진행성 비소세포폐암에서 ZD1839 ($Iressa^{TM}$)의 효과
Tuberculosis and Respiratory Diseases
2004 .01
-
대장암의 표적 치료
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2005 .12
-
Meta-analysis of Six Randomized Control Trials of Chemotherapy Plus Anti-HER Monoclonal Antibody for Advanced Gastric and Gastroesophageal Cancer
Asian Pacific journal of cancer prevention : APJCP
2014 .01
-
Frequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
비소세포암종의 Epidermal Growth Factor Receptor발현과 EGFR 돌연변이와의 관계
Journal of Pathology and Translational Medicine
2008 .01
-
Chemotherapy in Patients Older than or Equal to 75 Years with Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2012 .01
-
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Cancer Research and Treatment
2013 .01
-
폐암과 보험의학
보험의학회지
2012 .01
-
Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution
Tuberculosis and Respiratory Diseases
2014 .01
-
Intron 1 Polymorphism, Mutation and the Protein Expression of Epidermal Growth Factor Receptor in Relation to the Gefitinib Sensitivity of Korean Lung Cancer Patients
Journal of Pathology and Translational Medicine
2009 .01
-
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
Clinical Characteristics and Continued Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Administration in EGFR-Mutated Non-small Cell Lung Cancer with Skeletal Metastasis
Cancer Research and Treatment
2016 .01
-
비소세포폐암종에서 EGFR 단백 발현과 유전자 증폭이제피티닙 치료에 미치는 영향
Journal of Pathology and Translational Medicine
2008 .01
-
Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis
Asian Pacific journal of cancer prevention : APJCP
2012 .01
-
Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases
Asian Pacific journal of cancer prevention : APJCP
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0